Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 4/20 | 0.58 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | FLT4 | P35916 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977995 | 0.80 | KDR (0.62) | FLT1KDRKMT2AKITABL1 | |
| SCHEMBL4976797 | 0.78 | KDR (0.63) | FLT1KDRNPC1RAB9AALDH1A1 | |
| SCHEMBL4980032 | 0.77 | KDR (0.72) | FLT1KDRNPC1RAB9AMEN1 | |
| SCHEMBL4979656 | 0.76 | ADRA2C (0.67) | FLT1KDRMAPK1ALDH1A1HPGD | |
| SCHEMBL4977683 | 0.75 | KDR (0.71) | FLT1KDRKITABL1CSF1R | |
| SCHEMBL4033398 | 0.75 | NPC1 (0.49) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4983027 | 0.75 | KDR (0.59) | FLT1KDRRAB9AMAPTMEN1 | |
| SCHEMBL28650599 | 0.75 | MEN1 (0.66) | MAPK1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2229333 | 0.75 | KDR (0.67) | FLT1KDRKITABL1CSF1R | |
| SCHEMBL4038209 | 0.75 | NPC1 (0.50) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081468-B2 | Ortho-substituted anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2006-07-25 | — | — | US | claimed |
| US-20060014747-A1 | Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-19 | — | — | US | claimed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-7081468-B2 | Ortho-substituted anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2006-07-25 | — | — | US | disclosed |
| US-20060014747-A1 | Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-19 | — | — | US | disclosed |
| US-20040102441-A1 | Ortho-substituted anthranilic acid amides and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014747-A1 | Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents | VEGFA, TEK, OGFR | FLT1 11/4885KDR 4/4885MAPK1 1455/4885 |
| US-20040102441-A1 | Ortho-substituted anthranilic acid amides and their use as medicaments | TEK, VEGFA, ASPH | FLT1 24/4885KDR 30/4885MAPK1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.